![Οστεονέκρωση μηριαίας κεφαλής μετά από εξάρθρημα ισχίου με κάταγμα κοτύλης | 77ο Πανελλήνιο Συνέδριο ΕΕΧΟΤ Οστεονέκρωση μηριαίας κεφαλής μετά από εξάρθρημα ισχίου με κάταγμα κοτύλης | 77ο Πανελλήνιο Συνέδριο ΕΕΧΟΤ](https://eposters.betterevents.io/eexot2021/web/sites/default/files/pdfpreview/418-OSTEONEKROSI%20MIRIAIAS%20KEFALIS%20META%20APO%20EXARThRIMA%20ISHIOY%20ME%20KATAGMA%20KOTYLIS.png)
Οστεονέκρωση μηριαίας κεφαλής μετά από εξάρθρημα ισχίου με κάταγμα κοτύλης | 77ο Πανελλήνιο Συνέδριο ΕΕΧΟΤ
![Ioannis TIGKAS | Asst. Professor | PhD, CEng, MSc Fin., MSc, BEng | University of West Attica, Athens | TEIATH | Department of Naval Architecture Ioannis TIGKAS | Asst. Professor | PhD, CEng, MSc Fin., MSc, BEng | University of West Attica, Athens | TEIATH | Department of Naval Architecture](https://i1.rgstatic.net/ii/profile.image/1034600147066884-1623679305635_Q512/Ioannis-Tigkas.jpg)
Ioannis TIGKAS | Asst. Professor | PhD, CEng, MSc Fin., MSc, BEng | University of West Attica, Athens | TEIATH | Department of Naval Architecture
![Spyrou Philoxenia Introduces Skopelos to Serbian Travel Agents, Journalists | GTP Headlines | Travel agent, Skopelos, Travel Spyrou Philoxenia Introduces Skopelos to Serbian Travel Agents, Journalists | GTP Headlines | Travel agent, Skopelos, Travel](https://i.pinimg.com/originals/b9/fd/a9/b9fda93ec37328ca7090c095e52592dd.jpg)
Spyrou Philoxenia Introduces Skopelos to Serbian Travel Agents, Journalists | GTP Headlines | Travel agent, Skopelos, Travel
![PDF) Birds, stars and a homometric occurrence: the case of Alcm. frg. 3 Cal., vv. 87~101 | Alessio Faedda - Academia.edu PDF) Birds, stars and a homometric occurrence: the case of Alcm. frg. 3 Cal., vv. 87~101 | Alessio Faedda - Academia.edu](https://0.academia-photos.com/19326536/6256724/37045250/s200_alessio.faedda.jpg)
PDF) Birds, stars and a homometric occurrence: the case of Alcm. frg. 3 Cal., vv. 87~101 | Alessio Faedda - Academia.edu
![Kostas SPYROU | Professor | PhD | National Technical University of Athens, Athens | NTUA | School of Naval Architecture and Marine Engineering Kostas SPYROU | Professor | PhD | National Technical University of Athens, Athens | NTUA | School of Naval Architecture and Marine Engineering](https://i1.rgstatic.net/ii/profile.image/272261684920337-1441923652186_Q512/Kostas-Spyrou-3.jpg)
Kostas SPYROU | Professor | PhD | National Technical University of Athens, Athens | NTUA | School of Naval Architecture and Marine Engineering
![Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up - Langley - 2015 - Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up - Langley - 2015 -](https://onlinelibrary.wiley.com/cms/asset/0aa40934-60e9-4ed0-bb9f-95f3f098bbe5/bjd13469-fig-0006-m.jpg)
Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up - Langley - 2015 -
![Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up - Langley - 2015 - Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up - Langley - 2015 -](https://onlinelibrary.wiley.com/cms/asset/1b64e26e-70d7-4306-bdac-52136782c88f/bjd13469-fig-0002-m.jpg)
Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up - Langley - 2015 -
![Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up - Langley - 2015 - Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up - Langley - 2015 -](https://onlinelibrary.wiley.com/cms/asset/0dae3851-9a23-473d-bbb9-6a86aa4a983b/bjd.2015.172.issue-5.cover.jpg)